claudiximab
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00909025)
Timeline
Indications
Approved for
Mechanism of action
- Claudin-18BINDING AGENT
CLDN18 binding agent
Antibody drug conjugates (ADCs), coupled to a cytotoxic agent.
Against isoform 2 of Claudin-18.
- Claudin-18INHIBITOR
CLDN18 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- ChEMBLCHEMBL2109427 ↗
Also known as
- claudiximab
- claudiximab
- imab362
- imab-362
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03528629 | Phase 1 | May 17, 2018 | Astellas |
| NCT01671774 | Phase 1 | Aug 1, 2012 | Ganymed Pharmaceuticals AG |
| NCT01630083 | Phase 2 | Jun 1, 2012 | Ganymed Pharmaceuticals AG |
| NCT01197885 | Phase 2 | Sep 1, 2010 | Ganymed Pharmaceuticals AG |
| NCT00909025 | Phase 1 | May 1, 2009 | Ganymed Pharmaceuticals AG |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ganymed Pharmaceuticals AG | For profit | 4 | 4 | 2 | 2009 |
| Astellas | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1